20th SCI/RSC Medicinal Chemistry Symposium

Synopsis

The organisers invite you to the 20th SCI / RSC Medicinal Chemistry Symposium, Europe’s premier biennial Medicinal Chemistry event, focussing on first disclosures and new strategies in Medicinal Chemistry.

---

Attendees

This conference will be of interest to both academic and industrial scientists engaged in all aspects of the drug discovery and development process. 

---

Programme

Sunday 8 September 2019

13.30		Medicinal chemistry workshop (signed-up early-career delegates only)
15.00		Registration and refreshments
18.30		Welcome BBQ* (optional extra)
20.00		Drinks Mixer

Monday 9 September 2019

08.50		Welcome and opening remarks Nadia Ahmad, Charles River Laboratories, UK
09.00		Novel potent and selective 5HT2C receptor agonists for the treatment of neurological disorders Lynette Smyth, AbbVie, Germany
09.40		One binder, two effects. Context dependent inhibition or rescue of MALT1 protease Jean Quancard, Novartis Institutes for BioMedical Research, Switzerland
10.10		Resetting the antibacterial arms race: LepΒ as a novel gram-negative target James Crawford, Genentech, USA
10.40		Refreshments and exhibitors
11.10		The discovery of the selective orexin 1 receptor antagonist (SO- 1RA) ACT-539313 for the treatment of anxiety disorders Jodi Williams, Idorsia Pharmaceuticals, Switzerland
11.50		Discovery and disclosure of JNJ-61393215, a selective Orexin-1 Receptor Antagonist Brock T. Shireman, Janssen Research & Development, USA
12.20		Ventures in new target space: drugging the DUBs Tim Harrison, ALMAC, UK
12.50		Malcolm Campbell Memorial Prize presentation
13.05		Lunch
14.15		The investigation of small molecule inhibitors of PLD for the treatment of ALS Fang Gao, Biogen, USA
14.55		Imaging Mutant Huntingtin Aggregates: Development of Potential PET Ligands Michael Prime, Evotec, UK
15.25		Optimising molecular design Nathan Brown, BenevolentAI, UK
15.55		Refreshments and exhibitors
16.25		Flash poster presentations
16.50		Do we need to change the definition of hit-, lead- and drug-like properties? Michael Shultz, Novartis Institutes for Biomedical Research, USA
17.20		Rules are for the obedience of fools and guidance of the wise – an objective appraisal of best practices in medicinal chemistry over 40 years Rob Young, Blue Burgundy Ltd, UK
17.50		Poster session and reception
19.30		Churchill College Dinner* (optional extra)

 

Tuesday 10 September 2019

08.30		Discovery of PF-06882961: A potent, orally bioavailable small molecule agonist of the GLP-1 receptor David Edmonds, Pfizer, USA
09.10		Apelin: a multi-faceted GPCR and a target for the treatment of glioblastoma and pulmonary arterial hypertension Robert Glen, University of Cambridge, UK
09.40		Reactive (Cys-targeting) fragment libraries David House, GlaxoSmithkline, UK
10.10		Refreshments and exhibitors
10.40		Discovery of GS-9688, a selective toll-like receptor 8 agonist for hepatitis B cure Richard Mackman, Gilead Sciences, USA
11.10		Fragment-guided discovery of an irresistible antiviral protein-protein interaction inhibitor Ed Tate, Imperial College London, UK
11.40		A potent and selective PRMT5 inhibitor for the potential treatment of acute myeloid leukaemia Ylva Bozikis, Cancer Therapeutics CRC (CTx), Australia
11.55		Inhaled vs oral drug delivery for respiratory diseases: opportunities and challenges Elisa Pasqua, Charles River Laboratories, UK
12.10		Discovery of GSK701, a novel orally effective preclinical drug candidate for the treatment of malaria Maria Isabel Castellote Alvaro, GlaxoSmithKline, Tres Cantos, Spain
12.25		Lunch
13.35		Discovery and development of novel amidobenzimidazole (ABZI) STING agonists as cancer therapeutics Joshi Ramanjulu, GlaxoSmithKline, USA
14.15		The discovery of Cenerimod – a selective S1P1 receptor modulator in phase II clinical trials in SLE Martin Bolli, Idorsia Pharmaceuticals, Switzerland
14.45		Refreshments and exhibitors
15.15		Discovery of RDN-929, an HDAC-CoREST complex-selective inhibitor that promotes pro-synaptic integrity for therapeutic treatment of synaptopathies Nathan Fuller, Rodin Therapeutics, USA
15.45		The discovery of Kisqali® (ribociclib), a CDK4/6 inhibitor for the treatment of breast cancer Christopher Brain/Steven Howard, Novartis Institutes for Biomedical Research, USA /Astex Pharmaceuticals, UK
16.25		Flash poster presentations
16.50		Poster session II and refreshments
19.00		Drinks reception - Murray Edwards College (optional extra)
19.45		Gala dinner - Murray Edwards College* (optional extra)

 

Wednesday 11 September 2019

09.00		Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies Stefan Gradl, Bayer AG, Germany
09.40		Allosteric covalent inhibitors of the mutant GTPase KRASG12C Jason Kettle, AstraZeneca, UK
10.10		The challenges of drug discovery in Chagas disease Silvia Gonzalez-del Valle, GlaxoSmithKline, Spain
10.40		Refreshments and exhibitors
11.10		Discovery of LY3154207, a potent and selective dopamine receptor D1 positive allosteric modulator for the treatment of Parkinson’s disease dementia Junliang Hao, Eli Lilly and Co, USA
11.50		Discovery of pre-clinical candidate Calcitonin Gene- Related Peptide (CGRP) receptor antagonist HTL0022562 and an innovative new class of CGRP ligands John Christopher, Sosei-Heptares, UK
12.30		Lunch
13.40		Validation of a novel CNS target directly in humans: A case study Patrick Schnider, F. Hoffmann-La Roche Ltd., Switzerland
14.20		Discovery of novel positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor for the treatment of cognitive disorders Ian Bell, MSD, USA
14.50		Discovery of AZD7648, a potent and selective DNA-PK inhibitor Frederick W. Goldberg, AstraZeneca, UK
15:30		Closing remarks

 

* All optional extra dinners; BBQ, Churchill College Dinner and Gala Dinner, must be booked in advance of the conference.

---

Venue and Contact

---

Fees

---

Booking Process/Deadlines

For booking terms and conditions click here

---

Abstracts

Contributions from the whole field of medicinal chemistry are invited.  Flash presentation sessions are planned which will involve a two-minute presentation of poster highlights. Please submit A4 abstracts of your poster presentation to conferences@soci.org and indicate whether or not you would like to be included for consideration in the flash presentation session. The final deadline for submission of posters is Friday 26 July.

---

---

---

---

Exhibition and Sponsorship

Exhibition spaces are now sold out, but please contact conferences@soci.org for sponsorship options

---

Student Bursaries

A limited number of student bursaries are available to registered participants, as a contribution to the cost of registration fees, travel and accommodation. The closing date for applications is 26 July 2019, to receive an application form please email conferences@soci.org

---

Early Career Workshop

A satellite workshop consisting of a team-based exercise around a virtual medicinal chemistry programme will be held on the Sunday afternoon prior to this event, aimed at early career (up to 5 years’ experience) medicinal chemists. Registration for this event will be at no additional cost to the main meeting.

The workshop will consist of a team-based exercise around a virtual medicinal chemistry programme and will offer participants:

• Training in advanced medicinal chemistry
• Testing out leadership/decision making skills
• Networking between potential future leaders of different organisations
• Introductions of possible future collaborators from pharma, CRO, charity and SME    sectors
• Opportunity for informal interaction with experienced medicinal chemists workshop

Please email conferences@soci.org for further details and to reserve a place

---